ATE498631T1 - Glucagon-like-peptide-2- (glp-2-) analoga - Google Patents

Glucagon-like-peptide-2- (glp-2-) analoga

Info

Publication number: ATE498631T1
Authority: AT; Austria
Prior art keywords: glp; analogues; substitutions; positions; disclosed
Prior art date: 2005-05-04

Application number

AT06727006T

Other languages

English (en)

Inventor

Bjarne Larsen

Yvette Petersen

Kirsten Ebbehyj

Original Assignee

Zealand Pharma As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-04

Filing date

2006-05-04

Publication date

2011-03-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36649773&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE498631(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-05-04 Application filed by Zealand Pharma As filed Critical Zealand Pharma As

2011-03-15 Application granted granted Critical

2011-03-15 Publication of ATE498631T1 publication Critical patent/ATE498631T1/de

Links

229940121355 glucagon like peptide 2 (glp-2) analogues Drugs 0.000 title abstract 3
TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 abstract 4
238000006467 substitution reaction Methods 0.000 abstract 3
102400000326 Glucagon-like peptide 2 Human genes 0.000 abstract 1
101800000221 Glucagon-like peptide 2 Proteins 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
238000003556 assay Methods 0.000 abstract 1
230000004071 biological effect Effects 0.000 abstract 1
210000004899 c-terminal region Anatomy 0.000 abstract 1
238000002512 chemotherapy Methods 0.000 abstract 1
230000037430 deletion Effects 0.000 abstract 1
238000012217 deletion Methods 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
238000000338 in vitro Methods 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
230000000087 stabilizing effect Effects 0.000 abstract 1
210000002784 stomach Anatomy 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
238000011282 treatment Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20041—Use of virus, viral particle or viral elements as a vector
- C12N2710/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22041—Use of virus, viral particle or viral elements as a vector
- C12N2710/22043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20241—Use of virus, viral particle or viral elements as a vector
- C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Zoology (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Diabetes (AREA)
Biophysics (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Hematology (AREA)
Dermatology (AREA)
Developmental Biology & Embryology (AREA)
Reproductive Health (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Virology (AREA)
Microbiology (AREA)

AT06727006T 2005-05-04 2006-05-04 Glucagon-like-peptide-2- (glp-2-) analoga ATE498631T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US67806605P	2005-05-04	2005-05-04
PCT/GB2006/001633 WO2006117565A2 (en)	2005-05-04	2006-05-04	Glucagon-like-peptide-2 (glp-2) analogues

Publications (1)

Publication Number	Publication Date
ATE498631T1 true ATE498631T1 (de)	2011-03-15

Family

ID=36649773

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06727006T ATE498631T1 (de)	2005-05-04	2006-05-04	Glucagon-like-peptide-2- (glp-2-) analoga

Country Status (24)

Country	Link
US (7)	US7563770B2 (de)
EP (4)	EP2295451A1 (de)
JP (3)	JP5405105B2 (de)
KR (3)	KR101242951B1 (de)
CN (2)	CN101171262B (de)
AT (1)	ATE498631T1 (de)
AU (1)	AU2006242998B2 (de)
BR (1)	BRPI0610091B1 (de)
CA (1)	CA2607150C (de)
CY (1)	CY1111411T1 (de)
DE (1)	DE602006020123D1 (de)
DK (1)	DK1877435T4 (de)
EA (1)	EA014184B1 (de)
ES (1)	ES2361095T5 (de)
IL (3)	IL186746A (de)
MX (1)	MX2007013431A (de)
NO (1)	NO345236B1 (de)
NZ (4)	NZ593050A (de)
PL (1)	PL1877435T5 (de)
PT (1)	PT1877435E (de)
SI (1)	SI1877435T2 (de)
UA (1)	UA95235C2 (de)
WO (1)	WO2006117565A2 (de)
ZA (2)	ZA200709384B (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6057287A (en)	1994-01-11	2000-05-02	Dyax Corp.	Kallikrein-binding "Kunitz domain" proteins and analogues thereof
DK2311432T3 (en)	2002-06-07	2015-02-02	Dyax Corp	Modified Kunitz domain polypeptides and their use in reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure
US7153829B2 (en)	2002-06-07	2006-12-26	Dyax Corp.	Kallikrein-inhibitor therapies
TR201900937T4 (tr)	2002-08-28	2019-02-21	Dyax Corp	Organların ve dokuların muhafaza edilmesine yönelik yöntem.
US7235530B2 (en)	2004-09-27	2007-06-26	Dyax Corporation	Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
MX2007013431A (es) *	2005-05-04	2008-01-18	Zealand Pharma As	Analogos del peptido 2 semejante al glucagon.
EP2001500A4 (de) *	2006-03-10	2010-07-28	Dyax Corp	Formulierungen für ecallantid
PL2049142T5 (pl) †	2006-07-26	2016-09-30	Sandoz Ag	Preparaty kaspofunginy
WO2008031770A2 (en) *	2006-09-12	2008-03-20	Cosmo Technologies Ltd	Pharmaceutical compositions for the oral or rectal administration of protein substances
AU2007319066B2 (en)	2006-11-08	2013-09-19	Zealand Pharma A/S	Selective glucagon-like-peptide-2 (GLP-2) analogues
US20090004243A1 (en)	2007-06-29	2009-01-01	Pacetti Stephen D	Biodegradable triblock copolymers for implantable devices
KR20090035279A (ko) *	2007-10-05	2009-04-09	경희대학교 산학협력단	위장관 손상 예방 및 치료용 조성물
US20090110713A1 (en) *	2007-10-31	2009-04-30	Florencia Lim	Biodegradable polymeric materials providing controlled release of hydrophobic drugs from implantable devices
US8637454B2 (en)	2009-01-06	2014-01-28	Dyax Corp.	Treatment of mucositis with kallikrein inhibitors
CN102942626B (zh) *	2009-03-05	2015-11-04	江苏豪森医药集团有限公司	胰高血糖素样肽-2类似物及其制备方法和用途
EP2314616A1 (de)	2009-10-23	2011-04-27	Ferring B.V.	GLP-2-Peptid-Agonisten
ES2688093T3 (es)	2010-01-06	2018-10-30	Dyax Corp.	Proteínas de unión a calicreína plasmática
EP2611825B1 (de) *	2010-08-30	2015-09-02	NPS Pharmaceuticals, Inc.	Festphasensynthese von h(gly2)glp-2
IL269565B2 (en)	2011-01-06	2024-06-01	Dyax Corp	Plasma kallikrein binding proteins
CN102212127B (zh) *	2011-05-17	2015-02-04	上海景泽生物技术有限公司	胰高血糖素样肽-2聚乙二醇结合物及其制备方法和用途
CN102924589B (zh) *	2011-08-11	2016-08-24	中肽生化有限公司	胰高血糖素样肽-2(glp-2)的类似物及其制备方法和用途
EP3431098A1 (de)	2011-09-12	2019-01-23	Amunix Operating Inc.	Glucagonartige peptid-2-zusammensetzungen und verfahren zur herstellung und verwendung davon
KR101895047B1 (ko)	2011-12-30	2018-09-06	한미사이언스 주식회사	면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
CA2865578C (en)	2012-02-27	2023-01-17	Amunix Operating Inc.	Xten conjugate compositions and methods of making same
TR201802689T4 (tr)	2012-05-03	2018-03-21	Zealand Pharma As	Glukagon benzeri peptit-2 (glp-2) analogları.
US20150038674A1 (en) *	2013-08-05	2015-02-05	Bayrak Bertan Boran	Use of glp-2 analogues in pulmonary diseases for therapeutic purpose
EP3122782A4 (de)	2014-03-27	2017-09-13	Dyax Corp.	Zusammensetzungen und verfahren zur behandlung von diabetischem makulaödem
US20160067311A1 (en) *	2014-09-10	2016-03-10	Helsinn Healthcare Sa	Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea
US20170087216A1 (en) *	2015-09-17	2017-03-30	Helsinn Healthcare Sa	Therapeutic Uses of Elsiglutide
BR112018011622A2 (pt)	2015-12-11	2018-11-27	Dyax Corp	método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
CN107987170B (zh) *	2016-10-27	2018-12-18	浙江道尔生物科技有限公司	一种用于治疗肠道疾病的融合蛋白
WO2018104559A1 (en) *	2016-12-09	2018-06-14	Zealand Pharma A/S	Glp-1/glp-2 dual agonists
WO2018104558A1 (en) *	2016-12-09	2018-06-14	Zealand Pharma A/S	Acylated glp-1/glp-2 dual agonists
SG10201911851VA (en) *	2016-12-09	2020-02-27	Zealand Pharma As	Acylated glp-1/glp-2 dual agonists
MX2019006600A (es)	2016-12-09	2019-08-01	Zealand Pharma As	Agonistas duales de glp-1/glp-2.
WO2018142363A1 (en) *	2017-02-06	2018-08-09	Orbicular Pharmaceutical Technologies Private Limited	Ready to use compositions of glp-2 analogues through self-administrable devices
ES2894629T3 (es) *	2017-06-16	2022-02-15	Zealand Pharma As	Pautas posológicas para la administración de análogos del péptido 2 similar al glucagón (GLP-2)
EP3689898B1 (de) *	2017-09-28	2026-04-29	Hanmi Pharm. Co., Ltd.	Langwirkendes konjugat von glucagon-like-peptid-2 (glp-2)-derivat
WO2019086559A1 (fr)	2017-10-31	2019-05-09	Adocia	Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2020020904A1 (en)	2018-07-23	2020-01-30	Zealand Pharma A/S	Therapeutic uses of glp-2 agonists
EP3628683A1 (de) *	2018-09-28	2020-04-01	Zealand Pharma A/S	Formulierungen von analoga des glucagon-like-peptid-2 (glp-2)
EP3628682A1 (de)	2018-09-28	2020-04-01	Zealand Pharma A/S	Formulierungen von analoga des glucagon-like-peptid-2 (glp-2)
US20200254065A1 (en) *	2019-02-11	2020-08-13	Opko Biologics Ltd.	Long-acting glp-2 analogs
SG11202111312UA (en)	2019-06-14	2021-12-30	Zealand Pharma As	Pharmaceutical parenteral composition of dual glp1/2 agonist
CN110305223B (zh)	2019-06-26	2022-05-13	重庆派金生物科技有限公司	重组串联融合蛋白制备目标多肽的方法
BR112022006546A2 (pt)	2019-10-07	2022-08-30	Kallyope Inc	Agonistas de gpr119
CA3163507A1 (en)	2019-12-04	2021-06-10	The Scripps Research Institute	Peptide conjugates and methods of use
CA3167336A1 (en)	2020-01-13	2021-07-22	Takeda Pharmaceutical Company Limited	Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
CA3173731A1 (en)	2020-02-28	2021-09-02	Kallyope, Inc.	Gpr40 agonists
WO2021198195A1 (en)	2020-03-30	2021-10-07	Zealand Pharma A/S	Agonist combination
KR20210124071A (ko) *	2020-04-03	2021-10-14	한미약품 주식회사	Glp-2 유도체 또는 이의 지속형 결합체를 포함하는 방사선요법, 화학요법, 또는 이들의 조합으로 유발된 점막염의 예방 또는 치료용 약학적 조성물
CN116323608A (zh)	2020-05-19	2023-06-23	卡尔优普公司	Ampk活化剂
CN111560061A (zh) *	2020-05-26	2020-08-21	成都圣诺生物制药有限公司	一种Gelpaglutide的制备方法
CN111560062A (zh) *	2020-05-26	2020-08-21	成都圣诺生物制药有限公司	一种Elisiglutide的制备方法
KR20230038187A (ko)	2020-06-09	2023-03-17	벡티브바이오 에이지	아프라글루타이드의 제조, 제형화 및 투여
EP4172162A4 (de)	2020-06-26	2024-08-07	Kallyope, Inc.	Ampk-aktivatoren
AU2021401137B2 (en) *	2020-12-16	2024-09-05	Zealand Pharma A/S	Pharmaceutical composition of glp-1/glp-2 dual agonists
IL303088A (en)	2020-12-16	2023-07-01	Zealand Pharma As	Use of glp-2 analogues in patients with renal insufficiency
IL309067A (en)	2021-06-09	2024-02-01	Scripps Research Inst	Long-acting dual gip/glp-1 peptide conjugates and methods of use
CN115636876A (zh) *	2021-07-20	2023-01-24	重庆派金生物科技有限公司	胰高血糖素样肽-2突变体的定向化学偶联物及其应用
MX2024002569A (es)	2021-09-10	2024-04-30	Zealand Pharma As	Proceso para formular composiciones que comprenden analogos de peptido 2 similar a glucagon (glp-2).
CA3241692A1 (en)	2021-12-23	2023-06-29	Claes MELANDER	Processes for synthesizing glucagon-like-peptide 2 (glp-2) analogues
EP4572783A1 (de)	2022-09-30	2025-06-25	Zealand Pharma A/S	Analoga des glucagon-like-peptid-2 (glp-2) und ihre medizinische verwendung zur behandlung von kurzdarmsyndrom (sbs)
EP4654986A1 (de)	2023-01-27	2025-12-03	Zealand Pharma A/S	Analoga des glucagon-like-peptid-2 (glp-2) und ihre medizinische verwendung zur behandlung von kurzdarmsyndrom (sbs)
CN116478269A (zh) *	2023-04-28	2023-07-25	成都奥达生物科技有限公司	一种长效替度鲁肽化合物
CN118005766B (zh) *	2023-06-21	2024-09-27	杭州信海医药科技有限公司	一种Glepaglutide的固相合成方法
TW202535919A (zh)	2023-12-28	2025-09-16	丹麥商西蘭製藥公司	類升糖素肽2(glp-2)類似物之調配物及其用途
WO2025162422A1 (zh) *	2024-01-31	2025-08-07	杭州先为达生物科技股份有限公司	胰高血糖素样肽2衍生物及其应用
WO2025181330A1 (en)	2024-02-29	2025-09-04	Vectivbio Ag	Dosage regimens for glucagon-like peptide 2 (glp-2) analogs

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA811368B (en)	1980-03-24	1982-04-28	Genentech Inc	Bacterial polypedtide expression employing tryptophan promoter-operator
JP2961045B2 (ja)	1993-02-24	1999-10-12	日清製粉株式会社	腸管粘膜増強促進剤
US6184208B1 (en)	1994-06-29	2001-02-06	Immunotech Developments Inc.	Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
US5789379A (en)	1995-04-14	1998-08-04	Allelix Biopharmaceutical Inc.	Glucagon-like peptide-2 analogs
US5990077A (en)	1995-04-14	1999-11-23	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
US5834428A (en) *	1995-04-14	1998-11-10	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en)	1995-04-14	2001-02-06	Nps Allelix Corp.	Intestinotrophic glucagon-like peptide-2 analogs
DK1975177T3 (da) †	1996-03-01	2011-07-25	Novo Nordisk As	Appetitundertrykkende peptid, formuleringer dermed og anvendelse deraf
US5912229A (en)	1996-03-01	1999-06-15	Novo Nordisk Als	Use of a pharmaceutical composition comprising an appetite-suppressing peptide
EP0906338B1 (de) *	1996-04-12	2002-11-06	1149336 Ontario Inc.	Analoge des glucagon ähnlichen peptides -2
US5994500A (en)	1996-07-19	1999-11-30	1149336 Ontario Inc.	Antagonists of intestinotrophic GLP-2 peptides
US20020025933A1 (en)	1996-08-30	2002-02-28	Knudsen Liselotte Bjerre	GLP-2 derivatives
CZ295838B6 (cs)	1996-09-09	2005-11-16	Zealand Pharma A/S	Způsob výroby peptidů
US5952301A (en) *	1996-12-10	1999-09-14	1149336 Ontario Inc.	Compositions and methods for enhancing intestinal function
CA2236519C (en)	1997-05-02	2011-09-13	1149336 Ontario Inc.	Methods of enhancing functioning of the large intestine
US6051557A (en)	1997-05-16	2000-04-18	1149336 Ontario Inc.	Methods of enhancing functioning of the upper gastrointestinal tract
ES2210756T3 (es) †	1997-05-16	2004-07-01	1149336 Ontario Inc.	Utilizacion de agonistas del glp-2 para mejorar el funcionamiento del tracto gastrointestinal superior.
EP2823812A1 (de)	1998-02-02	2015-01-14	Trustees Of Tufts College	Dipeptidylpeptidase-IV-Hemmer zur Behandlung von Typ-II Diabetes
AU757658B2 (en)	1998-03-09	2003-02-27	Zealand Pharma A/S	Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
EP1076066A1 (de) *	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptide zur Senkung des Blutglukosespiegels
WO2001041779A2 (en)	1999-12-08	2001-06-14	1149336 Ontario Inc.	Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment
US7186683B2 (en)	2000-09-18	2007-03-06	Sanos Bioscience A/S	Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US7371721B2 (en)	2000-09-18	2008-05-13	Sanos Bioscience A/S	Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
WO2002022151A2 (en)	2000-09-18	2002-03-21	Osteometer Bio Tech A/S	Use of glp-1 and flp-2 peptides for treatment of bone disorders
WO2002066062A2 (en)	2001-02-01	2002-08-29	Drucker Daniel J	Enhancement of glp-2 activity
ATE396202T1 (de) *	2001-02-16	2008-06-15	Conjuchem Biotechnologies Inc	Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
JP2005506956A (ja) *	2001-06-01	2005-03-10	イーライ・リリー・アンド・カンパニー	長時間作用性ｇｌｐ−１製剤
WO2004035624A2 (en) *	2002-10-14	2004-04-29	Novo Nordisk A/S	Glucagon - like peptide - 2 variants
WO2004085471A2 (en) *	2003-03-24	2004-10-07	Novo Nordisk A/S	Glp-2 derivatives
KR101241862B1 (ko) *	2003-09-19	2013-03-13	노보 노르디스크 에이/에스	신규 ｇｌｐ-1 유도체
US7847061B2 (en) *	2004-11-01	2010-12-07	Nps Pharmaceuticals, Inc.	Treatment of short bowel syndrome patients with colon-in-continuity
MX2007013431A (es)	2005-05-04	2008-01-18	Zealand Pharma As	Analogos del peptido 2 semejante al glucagon.
AU2007319066B2 (en)	2006-11-08	2013-09-19	Zealand Pharma A/S	Selective glucagon-like-peptide-2 (GLP-2) analogues
EA020537B1 (ru)	2008-12-15	2014-11-28	Зилэнд Фарма А/С	Аналоги глюкагона
UY33462A (es)	2010-06-23	2012-01-31	Zealand Pharma As	Analogos de glucagon
KR102011924B1 (ko)	2011-05-18	2019-08-21	메더리스 다이어비티즈, 엘엘씨	인슐린 저항성에 대한 개선된 펩티드 제약

2006
- 2006-05-04 MX MX2007013431A patent/MX2007013431A/es active IP Right Grant
- 2006-05-04 PT PT06727006T patent/PT1877435E/pt unknown
- 2006-05-04 CA CA2607150A patent/CA2607150C/en not_active Expired - Lifetime
- 2006-05-04 JP JP2008509505A patent/JP5405105B2/ja not_active Expired - Lifetime
- 2006-05-04 WO PCT/GB2006/001633 patent/WO2006117565A2/en not_active Ceased
- 2006-05-04 NZ NZ593050A patent/NZ593050A/xx unknown
- 2006-05-04 AT AT06727006T patent/ATE498631T1/de active
- 2006-05-04 BR BRPI0610091-0A patent/BRPI0610091B1/pt active IP Right Grant
- 2006-05-04 NZ NZ591179A patent/NZ591179A/en not_active IP Right Cessation
- 2006-05-04 SI SI200630985T patent/SI1877435T2/sl unknown
- 2006-05-04 DE DE602006020123T patent/DE602006020123D1/de not_active Expired - Lifetime
- 2006-05-04 DK DK06727006.6T patent/DK1877435T4/da active
- 2006-05-04 EP EP10009231A patent/EP2295451A1/de not_active Withdrawn
- 2006-05-04 CN CN2006800152135A patent/CN101171262B/zh not_active Expired - Lifetime
- 2006-05-04 US US11/429,168 patent/US7563770B2/en not_active Expired - Lifetime
- 2006-05-04 UA UAA200713558A patent/UA95235C2/ru unknown
- 2006-05-04 KR KR1020117015195A patent/KR101242951B1/ko not_active Expired - Fee Related
- 2006-05-04 EP EP06727006.6A patent/EP1877435B2/de not_active Expired - Lifetime
- 2006-05-04 KR KR1020077028167A patent/KR101200227B1/ko not_active Expired - Lifetime
- 2006-05-04 AU AU2006242998A patent/AU2006242998B2/en not_active Expired
- 2006-05-04 NZ NZ591178A patent/NZ591178A/en not_active IP Right Cessation
- 2006-05-04 EP EP10009232A patent/EP2295452A1/de not_active Withdrawn
- 2006-05-04 EP EP18206332.1A patent/EP3473646A1/de active Pending
- 2006-05-04 KR KR1020117015196A patent/KR101242795B1/ko not_active Expired - Fee Related
- 2006-05-04 PL PL06727006T patent/PL1877435T5/pl unknown
- 2006-05-04 CN CN201210124331.7A patent/CN102659938B/zh not_active Expired - Fee Related
- 2006-05-04 ES ES06727006T patent/ES2361095T5/es not_active Expired - Lifetime
- 2006-05-04 NZ NZ562943A patent/NZ562943A/en not_active IP Right Cessation
- 2006-05-04 EA EA200702408A patent/EA014184B1/ru unknown
- 2006-11-09 US US11/595,496 patent/US7745403B2/en active Active
2007
- 2007-10-18 IL IL186746A patent/IL186746A/en active IP Right Grant
- 2007-10-31 ZA ZA2007/09384A patent/ZA200709384B/en unknown
- 2007-11-23 NO NO20076043A patent/NO345236B1/no unknown
2009
- 2009-12-21 US US12/643,261 patent/US8163696B2/en not_active Expired - Lifetime
- 2009-12-21 US US12/643,233 patent/US8263552B2/en not_active Expired - Lifetime
2011
- 2011-01-16 IL IL210668A patent/IL210668A/en active IP Right Grant
- 2011-01-16 IL IL210669A patent/IL210669A/en active IP Right Grant
- 2011-01-28 ZA ZA2011/00753A patent/ZA201100753B/en unknown
- 2011-05-05 CY CY20111100436T patent/CY1111411T1/el unknown
2012
- 2012-06-28 US US13/536,377 patent/US9125882B2/en not_active Expired - Lifetime
2013
- 2013-04-03 JP JP2013077830A patent/JP5876434B2/ja not_active Expired - Fee Related
2015
- 2015-09-08 US US14/847,938 patent/US9580487B2/en not_active Expired - Lifetime
- 2015-10-01 JP JP2015196105A patent/JP6272284B2/ja not_active Expired - Lifetime
2017
- 2017-01-20 US US15/411,649 patent/US20170137487A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20150368314A1 (en)	2015-12-24
KR20110093924A (ko)	2011-08-18
WO2006117565A2 (en)	2006-11-09
ZA201100753B (en)	2022-12-21
NZ591179A (en)	2012-06-29
KR101242795B1 (ko)	2013-03-12
US20110098222A1 (en)	2011-04-28
KR20080015827A (ko)	2008-02-20
UA95235C2 (en)	2011-07-25
US9580487B2 (en)	2017-02-28
JP6272284B2 (ja)	2018-01-31
BRPI0610091A2 (pt)	2008-12-09
CY1111411T1 (el)	2015-08-05
DK1877435T4 (da)	2021-03-29
IL186746A0 (en)	2008-02-09
US7745403B2 (en)	2010-06-29
JP2008539713A (ja)	2008-11-20
CN101171262B (zh)	2012-06-27
JP2013189436A (ja)	2013-09-26
CN101171262A (zh)	2008-04-30
EA200702408A1 (ru)	2008-10-30
DE602006020123D1 (de)	2011-03-31
IL210668A0 (en)	2011-03-31
IL210669A0 (en)	2011-03-31
NZ591178A (en)	2012-06-29
EA014184B1 (ru)	2010-10-29
WO2006117565A3 (en)	2007-01-11
JP5405105B2 (ja)	2014-02-05
NZ562943A (en)	2011-03-31
IL186746A (en)	2012-08-30
PL1877435T5 (pl)	2021-09-27
CA2607150C (en)	2014-08-05
AU2006242998B2 (en)	2012-03-22
BRPI0610091B1 (pt)	2021-08-03
DK1877435T3 (da)	2011-06-06
US20110152186A1 (en)	2011-06-23
US8163696B2 (en)	2012-04-24
NZ593050A (en)	2012-12-21
PT1877435E (pt)	2011-05-24
ZA200709384B (en)	2011-04-28
CN102659938B (zh)	2016-01-20
US20070117752A1 (en)	2007-05-24
EP1877435A2 (de)	2008-01-16
IL210668A (en)	2013-05-30
AU2006242998A1 (en)	2006-11-09
JP5876434B2 (ja)	2016-03-02
EP2295452A1 (de)	2011-03-16
EP1877435B2 (de)	2021-03-17
US8263552B2 (en)	2012-09-11
JP2016006125A (ja)	2016-01-14
PL1877435T3 (pl)	2011-07-29
KR101200227B1 (ko)	2012-11-13
CN102659938A (zh)	2012-09-12
US20120289466A1 (en)	2012-11-15
KR20110095397A (ko)	2011-08-24
EP3473646A1 (de)	2019-04-24
ES2361095T5 (es)	2021-11-23
US7563770B2 (en)	2009-07-21
US20070231308A1 (en)	2007-10-04
EP2295451A1 (de)	2011-03-16
US20170137487A1 (en)	2017-05-18
HK1108898A1 (en)	2008-05-23
SI1877435T1 (sl)	2011-05-31
ES2361095T3 (es)	2011-06-13
IL210669A (en)	2013-08-29
NO345236B1 (no)	2020-11-16
US9125882B2 (en)	2015-09-08
KR101242951B1 (ko)	2013-03-13
SI1877435T2 (sl)	2021-05-31
NO20076043L (no)	2008-02-04
EP1877435B1 (de)	2011-02-16
MX2007013431A (es)	2008-01-18
CA2607150A1 (en)	2006-11-09

Legal Events

Date

Code

Title

Description

2011-08-15

UEP

Publication of translation of european patent specification

Ref document number: 1877435

Country of ref document: EP

Publication	Publication Date	Title
DE602006020123D1 (de)	2011-03-31	Glucagon-like-peptide-2- (glp-2-) analoga
MX2009004701A (es)	2009-05-21	Analogos selectivos del peptido 2 similar al glucagon.
BRPI0811320A2 (pt)	2014-10-21	Surfactantes reconstituídos com propriedades melhoradas
PE20120358A1 (es)	2012-04-26	Mutantes fgf21 y usos de los mismos
PE20191716A1 (es)	2019-12-05	Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
ATE417595T1 (de)	2009-01-15	Keratin-bindende polypeptide
AR067972A1 (es)	2009-10-28	Composiciones de fenilalaninamoniacoliasa de procariontes y uso de sus composiciones en metodos para tratar cancer
BR0012926A (pt)	2002-04-30	Polipeptìdeos quiméricos, método para a sua produção e seus usos
PE20120021A1 (es)	2012-02-10	Mutantes fgf21
AR113422A2 (es)	2020-04-29	Agentes tensioactivos reconstituidos que tienen propiedades mejoradas
NO20081654L (no)	2008-04-03	Stabiliserte GLP-1-analoger
NZ593190A (en)	2013-01-25	Factor viii formulations
WO2011038900A3 (en)	2011-06-23	Peptide analogues of glucagon for diabetes therapy
WO2009030498A3 (en)	2009-04-23	Use of gip for the treatment of disorders associated with dysfunctional synaptic transmission
BRPI0813619A2 (pt)	2020-01-14	peptídeos surfactantes pulmonares sintéticos
WO2006097432A3 (de)	2007-04-19	Keratin-biktdende desmoplakinpolypeptidsequenzen
DE60118418D1 (de)	2006-05-18	Maurotoxin, pi1 und hstx1 derivate
UA91178C2 (ru)	2010-07-12	Мутантный неубластин